Universal Biosensors, Inc. (ASX: UBI) today announced that LifeScan, Inc. has launched the OneTouch® VerioTM IQ system in the United States.  The launch represents a major milestone in the global roll-out of the OneTouch®  Verio TM  technology.  The OneTouch Verio system is now available in all major self monitoring blood glucose (SMBG) markets including the United States, Canada, Europe and Australia.  The continuing global roll-out further demonstrates LifeScan’s commitment to the OneTouch Verio technology.  

The SMBG market in the US in 2010 was approximately US$3.84bn which represents approximately 40%  of the global market.  The US SMBG market is expected to grow to US$5.59bn by 2015.   LifeScan is the market leader in North America with approximately 33% of the SMBG market in 2008.   UBI CEO, Paul Wright said, “this is an extremely significant milestone in the development of UBI’s business  and the commercialisation of its world-leading point of care diagnostics technology. The SMBG market in  the US is the single largest diagnostics market in the world.”  UBI manufactures test strips for the OneTouch Verio system in its Rowville (Melbourne) facility.  

Source: UBI